DRESS syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D., Serge Korjian M.D.

Overview

There are no established measures for the primary prevention of DRESS syndrome. Primary prevention measures may include slow dose escalation of drugs (e.g. anticonvulsants), genetic counseling, and in vitro impaired detoxification testing.

Primary Prevention

There are no established measures for the primary prevention of DRESS syndrome. Primary prevention measures may include the following:^[1]

Slow dose escalation of agents known to be associated with DRESS syndrome^[2]
Genetic counseling to relatives of patients with DRESS syndrome^[3]
In vitro impaired detoxification testing using lymphocyte toxicity assays among individuals with affected first-degree relatives^[3]

References

↑ Tas S, Simonart T (2003). “Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update”. Dermatology. 206 (4): 353–6. doi:69956 Check |doi= value (help). PMID 12771485.
↑ Fitton A, Goa KL (1995). “Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy”. Drugs. 50 (4): 691–713. PMID 8536554.
↑ ^3.0 ^3.1 Sullivan JR, Shear NH (2000). “What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions?”. Br J Dermatol. 142 (2): 205–7. PMID 10730749.

Template:WS Template:WH

[pmid12771485-1] Tas S, Simonart T (2003). “Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update”. Dermatology. 206 (4): 353–6. doi:69956 Check |doi= value (help). PMID 12771485.

[pmid8536554-2] Fitton A, Goa KL (1995). “Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy”. Drugs. 50 (4): 691–713. PMID 8536554.

[pmid10730749-3] 3.0 ^3.1 Sullivan JR, Shear NH (2000). “What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions?”. Br J Dermatol. 142 (2): 205–7. PMID 10730749.

[1]

[2]

[3]